What is Amador Bioscience?
Founded in 2018 and headquartered in Pleasanton, California, Amador Bioscience operates as a specialized Transnational and Clinical Pharmacology Contract Research Organization (CRO). The firm provides a comprehensive suite of services, including GLP/GCLP bioanalysis, quantitative clinical pharmacology, and end-to-end regulatory filing support. By serving as a strategic partner to leading biopharmaceutical entities, Amador Bioscience bridges the gap between early-stage drug development and commercialization, ensuring that complex clinical data meets the stringent requirements of global health authorities.
How much funding has Amador Bioscience raised?
Amador Bioscience has raised a total of $60M across 1 funding round:
Series B
$60M
Series B (2021): $60M with participation from Co-win Ventures, MSA Capital, GL Ventures, Sequoia Capital, and CMB International Capital
Key Investors in Amador Bioscience
MSA Capital
MSA Capital is an independent global private equity and venture capital firm with over $1.5 billion under management, focusing on partnering with innovative entrepreneurs to deliver strong financial returns.
GL Ventures
GL Ventures is a specialized consulting and investment firm that collaborates with CEOs and board members to facilitate growth strategies and organizational transitions for emerging companies.
Sequoia Capital
Sequoia Capital is a premier global venture capital firm with an unparalleled track record of partnering with entrepreneurs to create market-leading companies across the technology and healthcare sectors.
What's next for Amador Bioscience?
With the successful closure of its latest funding round, Amador Bioscience is poised to accelerate its strategic growth initiatives. The company is expected to focus on enhancing its technical infrastructure and expanding its global laboratory capacity to meet the rising demand for high-fidelity clinical data. As the biopharmaceutical industry faces increasing pressure to shorten development timelines, Amador's focus on quantitative pharmacology and regulatory excellence will likely serve as a primary driver for its future market penetration. The firm is well-positioned to leverage its current momentum to secure further partnerships and solidify its status as a critical service provider in the global drug development ecosystem.
See full Amador Bioscience company page
